Relugolix — Discount Pricing
Relugolix is not confirmed for no-additional-cost pricing. Discount pricing may be available; confirm the price with the dispensing pharmacy.
Relugolix Pricing
| Pricing type | Price |
|---|---|
| TheDrugClub | Discount pricing may be available |
| Typical Retail | $125.00 |
Discount pricing may be available; confirm the price with the dispensing pharmacy.
About Relugolix
Relugolix is a prescription medication. Ask your doctor if Relugolix is right for you.
How to Check Relugolix Pricing
- Join TheDrugClub for $19.95/month
- Receive your member card by email
- Present your card at a participating pharmacy
- Check active-formulary eligibility or available discount pricing
Relugolix at Participating Pharmacies
- CVS Pharmacy
- Walgreens
- Walmart Pharmacy
- Rite Aid
- Kroger Pharmacy
- Costco Pharmacy
- Albertsons
- Safeway
- Publix Pharmacy
- H-E-B Pharmacy
Pharmacy participation and fulfillment options vary. Present your membership card and confirm current pricing before filling.
Other medications in Women's Health
What Relugolix is approved for (FDA label)
ORGOVYX is indicated for the treatment of adult patients with advanced prostate cancer. ORGOVYX is a gonadotropin-releasing hormone (GnRH) receptor antagonist indicated for the treatment of adult patients with advanced prostate cancer ( 1 ).
Source: Read the full FDA label on DailyMed. Label effective date: October 10, 2025.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.
Dosage forms and strengths for Relugolix (FDA label)
Tablets: 120 mg, light red, almond-shaped, film-coated, and debossed with “R” on one side and “120” on the other side. Tablets: 120 mg ( 3 ).
Source: FDA prescribing information (DailyMed). Set ID: 077a92f6-9f1b-479a-87c7-c92b5db6aa9c. SPL document ID: 0d9200dd-878e-4e93-98af-e1149e84c21f. Label effective date: October 10, 2025. Read the full label.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.
Adverse reactions for Relugolix (FDA label)
The following clinically significant adverse reactions are described elsewhere in the labeling: QT/QTc Interval Prolongation [see Warnings and Precautions ( 5.1 )] . The most common adverse reactions (≥ 10%) and laboratory abnormalities (≥ 15%) were hot flush, glucose increased, triglycerides increased, musculoskeletal pain, hemoglobin decreased, alanine aminotransferase (ALT) increased, fatigue, aspartate aminotransferase (AST) increased, constipation, and diarrhea ( 6.1 ).
Source: FDA prescribing information (DailyMed). Set ID: 077a92f6-9f1b-479a-87c7-c92b5db6aa9c. SPL document ID: 0d9200dd-878e-4e93-98af-e1149e84c21f. Label effective date: October 10, 2025. Read the full label.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.
Contraindications for Relugolix (FDA label)
ORGOVYX is contraindicated in patients with severe hypersensitivity to relugolix or to any of the product components. Known severe hypersensitivity to relugolix or to any of the product components ( 4 ).
Source: FDA prescribing information (DailyMed). Set ID: 077a92f6-9f1b-479a-87c7-c92b5db6aa9c. SPL document ID: 0d9200dd-878e-4e93-98af-e1149e84c21f. Label effective date: October 10, 2025. Read the full label.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.
Warnings and precautions for Relugolix (FDA label)
QT/QTc Interval Prolongation: Androgen deprivation therapy may prolong the QT interval ( 5.1 ). Hypersensitivity: ORGOVYX can cause hypersensitivity reactions, including angioedema. Withhold ORGOVYX in patients who experience symptoms of hypersensitivity. Discontinue ORGOVYX for severe hypersensitivity reactions and manage as clinically indicated ( 5.2 ). Embryo-Fetal Toxicity: ORGOVYX can cause fetal harm. Advise males with female partners of reproductive potential to use effective contraception ( 5.3 , 8.1 , 8.3 ). 5.1 QT/QTc Interval Prolongation Androgen deprivation therapy, such as ORGOVYX, may prolong the QT/QTc interval. Providers should consider whether the benefits of androgen deprivation therapy outweigh the potential risks in patients with congenital long QT syndrome, congestive heart failure, or frequent electrolyte abnormalities and in patients taking drugs known to prolong the QT interval. Electrolyte abnormalities should be corrected.
Source: FDA prescribing information (DailyMed). Set ID: 077a92f6-9f1b-479a-87c7-c92b5db6aa9c. SPL document ID: 0d9200dd-878e-4e93-98af-e1149e84c21f. Label effective date: October 10, 2025. Read the full label.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.
Drug interactions for Relugolix (FDA label)
P-gp Inhibitors: Avoid co-administration. If unavoidable, take ORGOVYX first, separate dosing by at least 6 hours, and monitor patients more frequently for adverse reactions ( 2.2 , 7.1 ). Combined P-gp and Strong CYP3A Inducers: Avoid co-administration. If unavoidable, increase the ORGOVYX dose to 240 mg once daily ( 2.3 , 7.1 ). 7.1 Effect of Other Drugs on ORGOVYX P-gp Inhibitors Relugolix is a P-gp substrate. Co-administration of ORGOVYX with an oral P-gp inhibitor increases relugolix exposure [see Clinical Pharmacology ( 12.3 )], which may increase the risk of adverse reactions associated with ORGOVYX. Avoid co-administration of ORGOVYX with oral P-gp inhibitors. If co-administration with an oral P-gp inhibitor cannot be avoided, take ORGOVYX first and separate dosing by at least 6 hours.
Source: FDA prescribing information (DailyMed). Set ID: 077a92f6-9f1b-479a-87c7-c92b5db6aa9c. SPL document ID: 0d9200dd-878e-4e93-98af-e1149e84c21f. Label effective date: October 10, 2025. Read the full label.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.